Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells

12 Dec 2018

Abstract excerpt

Large clinical trials demonstrated that SGLT2 inhibitors (SGLT2i) slow the progression of kidney function decline in type 2 diabetes. Because the underlying molecular mechanisms are largely unknown, we studied the effects of SGLT2i on gene expression in two human proximal tubular (PT) cell lines under normoglycemic conditions, utilizing two SGLT2i, namely empagliflocin and canagliflocin. Genome-wide expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Kidney Disease and Diabetes
Share to Diabetes Treatment and Management
Share to Renal Diseases and Glomerulopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30539648
DOI: 10.1152/ajprenal.00431.2018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cellsPMID 30539648Read ↗

SGLT2 transcriptomic expression atlas supports a kidney-centric role for empagliflozin’s benefits in heart failureSemantic proximity Read ↗

SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2Semantic proximity Read ↗

Comprehensive circRNA Expression Profile and Transcriptomics-Based Molecular Pathway Analysis of the Sodium-Glucose Co-Transporter-2 Inhibitor Dapagliflozin in Diabetic Tubular Epithelial CellsSemantic proximity Read ↗

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes: An Umbrella ReviewSemantic proximity Read ↗

Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization studySemantic proximity Read ↗

SGLT2 inhibition mitigates perturbations in nephron segment-specific metabolic transcripts and mTOR pathway activity in kidneys of young persons with type 2 diabetesSemantic proximity Read ↗

Kidney single-cell transcriptomes uncover SGLT2i-induced metabolic reprogramming via restoring glycolysis and fatty acid oxidationSemantic proximity Read ↗

Development of SGLT1 and SGLT2 inhibitors.Semantic proximity Read ↗

Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney diseaseSemantic proximity Read ↗

The effect of SGLT2 inhibitor on the gene expression and metabolomic profile of podocytesSemantic proximity Read ↗

Efficacy and safety of SGLT2 inhibitors in the treatment of heart failure-May raise creatinine levels in patients: A meta-analysisSemantic proximity Read ↗

Targeting High Glucose-Induced Epigenetic Modifications at Cardiac Levels: The Role of SGLT2 and SGLT2 InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.